1 – 10 of 56
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Second- and Third-Line Salvage Chemotherapy Followed by Allogeneic Stem Cell Transplantation Leads to High Survival Rates in Primary Refractory AML—A Population-Based Study
2025) In European Journal of Haematology(
- Contribution to journal › Article
- 2024
-
Mark
Effectiveness of R-CHOP versus R-CHOEP for treatment of young patients with high-risk diffuse large B-cell lymphoma : A Danish observational population-based study
(
- Contribution to journal › Article
- 2023
-
Mark
Impact of 1q gains on treatment outcomes of patients with newly diagnosed multiple myeloma in a real-world Swedish population receiving modern treatment
(
- Contribution to journal › Article
- 2022
-
Mark
Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries
(
- Contribution to journal › Article
-
Mark
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma : A randomised phase 2 trial by the Nordic Myeloma Study Group
(
- Contribution to journal › Article
-
Mark
Survival and risk of vascular complications in myelofibrosis—A population-based study from the Swedish MPN group
(
- Contribution to journal › Article
- 2021
-
Mark
Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma
(
- Contribution to journal › Article
-
Mark
Untangling fracture risk in monoclonal gammopathy of undetermined significance : A population-based cohort study
(
- Contribution to journal › Article
-
Mark
Letter to the Editor : Fine-needle aspiration cytology and core-needle biopsy in the diagnosis of lymphadenopathies: Words of endorsement
(
- Contribution to journal › Article
-
Mark
Comorbidities in multiple myeloma and implications on survival : A population-based study
(
- Contribution to journal › Article